MovDisordV3, Main, Merge, bibRecord, 002E86

Neuroprotection Trials in Parkinson's Disease : Systematic Review

Identifieur interne : 002E86 ( Main/Merge ); précédent : 002E85; suivant : 002E87

Neuroprotection Trials in Parkinson's Disease : Systematic Review

Auteurs : Robert G. Hart [États-Unis] ; Lesly A. Pearce ; Bernard M. Ravina [États-Unis] ; Toby C. Yaltho [États-Unis] ; John R. Marler [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2009.

RBID : Pascal:09-0218137

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Essai clinique.

English descriptors

KwdEn :
- Clinical trial, Nervous system diseases, Parkinson disease.

Abstract

Treatments to slow the progression are a major unmet need in Parkinson's disease. Detailed assessment of randomized trials testing putative neuroprotective drugs was undertaken to inform the design, reporting, and interpretation of future studies. This study is a systematic review of trials testing neuroprotective drugs. Data were extracted independently by two coauthors. Fifteen completed, published trials involving 4,087 participants tested 13 different drugs in 18 double-blind comparisons with placebo. Seven comparisons involving 2,000 subjects assessed MAO-B inhibitors. The primary outcome was change in the Unified Parkinson's Disease Rating Scale score in eight trials and time to need for dopaminergic therapy in seven. Mean participant age was 62 years, 35% were women, the interval from diagnosis to entry averaged 11 months, and the number of participants averaged 272 (largest = 806). Follow-up averaged <16 months in all but two trials. Detailed randomization methods and success of double-blinding were reported in 20% and 13%, respectively. Based on the investigators' conclusions, six trials were interpreted as consistent with a neuroprotective effect, three as negative, and five as either confounded or not meeting criteria for futility. Neuroprotection trials have involved relatively uniform groups of participants early in the clinical disease course, with outcomes weighted heavily toward motor deterioration. Future trials should include participants with wider ranges of disease stages and assess broader neurological outcomes.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000F24
to stream PascalFrancis, to step Curation: 001D95
to stream PascalFrancis, to step Checkpoint: 000D89

Links to Exploration step

Pascal:09-0218137

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Neuroprotection Trials in Parkinson's Disease : Systematic Review</title>
<author><name sortKey="Hart, Robert G" sort="Hart, Robert G" uniqKey="Hart R" first="Robert G." last="Hart">Robert G. Hart</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of Texas Health Science Center</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pearce, Lesly A" sort="Pearce, Lesly A" uniqKey="Pearce L" first="Lesly A." last="Pearce">Lesly A. Pearce</name>
</author>
<author><name sortKey="Ravina, Bernard M" sort="Ravina, Bernard M" uniqKey="Ravina B" first="Bernard M." last="Ravina">Bernard M. Ravina</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Depaivotent of Neurology, University of Rochester School of Medicine</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yaltho, Toby C" sort="Yaltho, Toby C" uniqKey="Yaltho T" first="Toby C." last="Yaltho">Toby C. Yaltho</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of Texas Health Science Center</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marler, John R" sort="Marler, John R" uniqKey="Marler J" first="John R." last="Marler">John R. Marler</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0218137</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0218137 INIST</idno>
<idno type="RBID">Pascal:09-0218137</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000F24</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001D95</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000D89</idno>
<idno type="wicri:doubleKey">0885-3185:2009:Hart R:neuroprotection:trials:in</idno>
<idno type="wicri:Area/Main/Merge">002E86</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Neuroprotection Trials in Parkinson's Disease : Systematic Review</title>
<author><name sortKey="Hart, Robert G" sort="Hart, Robert G" uniqKey="Hart R" first="Robert G." last="Hart">Robert G. Hart</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of Texas Health Science Center</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pearce, Lesly A" sort="Pearce, Lesly A" uniqKey="Pearce L" first="Lesly A." last="Pearce">Lesly A. Pearce</name>
</author>
<author><name sortKey="Ravina, Bernard M" sort="Ravina, Bernard M" uniqKey="Ravina B" first="Bernard M." last="Ravina">Bernard M. Ravina</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Depaivotent of Neurology, University of Rochester School of Medicine</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yaltho, Toby C" sort="Yaltho, Toby C" uniqKey="Yaltho T" first="Toby C." last="Yaltho">Toby C. Yaltho</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of Texas Health Science Center</s1>
<s2>San Antonio, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Marler, John R" sort="Marler, John R" uniqKey="Marler J" first="John R." last="Marler">John R. Marler</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>National Institute of Neurological Disorders and Stroke, National Institutes of Health</s1>
<s2>Bethesda, Maryland</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical trial</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Essai clinique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Treatments to slow the progression are a major unmet need in Parkinson's disease. Detailed assessment of randomized trials testing putative neuroprotective drugs was undertaken to inform the design, reporting, and interpretation of future studies. This study is a systematic review of trials testing neuroprotective drugs. Data were extracted independently by two coauthors. Fifteen completed, published trials involving 4,087 participants tested 13 different drugs in 18 double-blind comparisons with placebo. Seven comparisons involving 2,000 subjects assessed MAO-B inhibitors. The primary outcome was change in the Unified Parkinson's Disease Rating Scale score in eight trials and time to need for dopaminergic therapy in seven. Mean participant age was 62 years, 35% were women, the interval from diagnosis to entry averaged 11 months, and the number of participants averaged 272 (largest = 806). Follow-up averaged <16 months in all but two trials. Detailed randomization methods and success of double-blinding were reported in 20% and 13%, respectively. Based on the investigators' conclusions, six trials were interpreted as consistent with a neuroprotective effect, three as negative, and five as either confounded or not meeting criteria for futility. Neuroprotection trials have involved relatively uniform groups of participants early in the clinical disease course, with outcomes weighted heavily toward motor deterioration. Future trials should include participants with wider ranges of disease stages and assess broader neurological outcomes.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
<li>Texas</li>
<li>État de New York</li>
</region>
</list>
<tree><noCountry><name sortKey="Pearce, Lesly A" sort="Pearce, Lesly A" uniqKey="Pearce L" first="Lesly A." last="Pearce">Lesly A. Pearce</name>
</noCountry>
<country name="États-Unis"><region name="Texas"><name sortKey="Hart, Robert G" sort="Hart, Robert G" uniqKey="Hart R" first="Robert G." last="Hart">Robert G. Hart</name>
</region>
<name sortKey="Marler, John R" sort="Marler, John R" uniqKey="Marler J" first="John R." last="Marler">John R. Marler</name>
<name sortKey="Ravina, Bernard M" sort="Ravina, Bernard M" uniqKey="Ravina B" first="Bernard M." last="Ravina">Bernard M. Ravina</name>
<name sortKey="Yaltho, Toby C" sort="Yaltho, Toby C" uniqKey="Yaltho T" first="Toby C." last="Yaltho">Toby C. Yaltho</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E86 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002E86 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     Pascal:09-0218137
   |texte=   Neuroprotection Trials in Parkinson's Disease : Systematic Review
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Neuroprotection Trials in Parkinson's Disease : Systematic Review

Neuroprotection Trials in Parkinson's Disease : Systematic Review

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri